HYALGAN is a brand of sodium hyaluronate (HA) injections used to treat osteoarthritis (OA) of the knee. It was first launched in Europe in 1987 and was approved by the FDA in the United States in 1997. HYALGAN is manufactured by Fidia Farmaceutici, an Italian pharmaceutical company headquartered in Abano Terme, Italy.
HYALGAN is produced through a proprietary process that ensures high purity and efficacy. In 2011, Fidia regained full commercial rights to HYALGAN in the United States and began promoting, distributing, and selling the product through its subsidiary, Fidia Pharma USA Inc.